Application of random effects models and other methods to the analysis of multidimensional quality of life data in an AIDS clinical trial

Albert W Wu, Sarah M. Gray, Ronald Brookmeyer

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Current analytic methods applied to multidimensional health-related quality of life (HRQOL) data do not borrow strength across analyses and do not produce summary estimates of effect. OBJECTIVES. To compare a random effects modelling approach for the analysis of multidimensional HRQOL data to the following: (1) separate analyses for each dimension; (2) O'Brien's global test procedure; and (3) multivariate analysis of variance (MANOVA). RESEARCH DESIGN. Randomized clinical trial comparing 3 treatments (Trimethoprim-Sulfamethoxazole [TS], Dapsone-Trimethoprim [DT], and Clindamycin-Primaquine [CP] for Pneumocystis carinii pneumonia [PCP]). SUBJECTS. Patients with PCP enrolled in AIDS Clinical Trials Group Protocol 108. MEASURES. A 33-item battery assessing 7 dimensions of HRQOL: physical functioning, pain, energy, general health perceptions, disability, pulmonary symptoms, and constitutional symptoms. RESULTS. Analyses focused on changes in score from baseline to Day 7 (n = 145). Separate analyses for each dimension suggested a trend favoring CP versus TS, but using a Bonferroni correction no differences were statistically significant. O'Brien's global procedure for a test of no-treatment effect versus superiority of one treatment yielded P = 0.07. MANOVA did not reveal significant differences among treatment groups. A random effects model using fixed treatment and dimension effects and separate random effects for each person showed a significant overall treatment effect (P = 0.02); changes in scores for CP averaged 10 points greater than for TS. CONCLUSIONS. Random-effects models provide a flexible class of models for analyzing multidimensional quality of life data and estimating treatment effects because they borrow strength across dimensions.

Original languageEnglish (US)
Pages (from-to)249-258
Number of pages10
JournalMedical Care
Volume37
Issue number3
DOIs
StatePublished - Mar 1999

Fingerprint

quality of life
Acquired Immunodeficiency Syndrome
AIDS
Quality of Life
Clinical Trials
Primaquine
Clindamycin
Sulfamethoxazole Drug Combination Trimethoprim
Pneumocystis Pneumonia
Therapeutics
Analysis of Variance
Multivariate Analysis
health
analysis of variance
multivariate analysis
Dapsone
Trimethoprim
Clinical Protocols
Randomized Controlled Trials
pain

Keywords

  • Analytic methods
  • Clinical trial
  • HIV/AIDS
  • Quality of life
  • Random effects

ASJC Scopus subject areas

  • Nursing(all)
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Health Professions(all)

Cite this

Application of random effects models and other methods to the analysis of multidimensional quality of life data in an AIDS clinical trial. / Wu, Albert W; Gray, Sarah M.; Brookmeyer, Ronald.

In: Medical Care, Vol. 37, No. 3, 03.1999, p. 249-258.

Research output: Contribution to journalArticle

@article{c32b7918ad4e42afbb7d938c714e53e0,
title = "Application of random effects models and other methods to the analysis of multidimensional quality of life data in an AIDS clinical trial",
abstract = "BACKGROUND. Current analytic methods applied to multidimensional health-related quality of life (HRQOL) data do not borrow strength across analyses and do not produce summary estimates of effect. OBJECTIVES. To compare a random effects modelling approach for the analysis of multidimensional HRQOL data to the following: (1) separate analyses for each dimension; (2) O'Brien's global test procedure; and (3) multivariate analysis of variance (MANOVA). RESEARCH DESIGN. Randomized clinical trial comparing 3 treatments (Trimethoprim-Sulfamethoxazole [TS], Dapsone-Trimethoprim [DT], and Clindamycin-Primaquine [CP] for Pneumocystis carinii pneumonia [PCP]). SUBJECTS. Patients with PCP enrolled in AIDS Clinical Trials Group Protocol 108. MEASURES. A 33-item battery assessing 7 dimensions of HRQOL: physical functioning, pain, energy, general health perceptions, disability, pulmonary symptoms, and constitutional symptoms. RESULTS. Analyses focused on changes in score from baseline to Day 7 (n = 145). Separate analyses for each dimension suggested a trend favoring CP versus TS, but using a Bonferroni correction no differences were statistically significant. O'Brien's global procedure for a test of no-treatment effect versus superiority of one treatment yielded P = 0.07. MANOVA did not reveal significant differences among treatment groups. A random effects model using fixed treatment and dimension effects and separate random effects for each person showed a significant overall treatment effect (P = 0.02); changes in scores for CP averaged 10 points greater than for TS. CONCLUSIONS. Random-effects models provide a flexible class of models for analyzing multidimensional quality of life data and estimating treatment effects because they borrow strength across dimensions.",
keywords = "Analytic methods, Clinical trial, HIV/AIDS, Quality of life, Random effects",
author = "Wu, {Albert W} and Gray, {Sarah M.} and Ronald Brookmeyer",
year = "1999",
month = "3",
doi = "10.1097/00005650-199903000-00005",
language = "English (US)",
volume = "37",
pages = "249--258",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Application of random effects models and other methods to the analysis of multidimensional quality of life data in an AIDS clinical trial

AU - Wu, Albert W

AU - Gray, Sarah M.

AU - Brookmeyer, Ronald

PY - 1999/3

Y1 - 1999/3

N2 - BACKGROUND. Current analytic methods applied to multidimensional health-related quality of life (HRQOL) data do not borrow strength across analyses and do not produce summary estimates of effect. OBJECTIVES. To compare a random effects modelling approach for the analysis of multidimensional HRQOL data to the following: (1) separate analyses for each dimension; (2) O'Brien's global test procedure; and (3) multivariate analysis of variance (MANOVA). RESEARCH DESIGN. Randomized clinical trial comparing 3 treatments (Trimethoprim-Sulfamethoxazole [TS], Dapsone-Trimethoprim [DT], and Clindamycin-Primaquine [CP] for Pneumocystis carinii pneumonia [PCP]). SUBJECTS. Patients with PCP enrolled in AIDS Clinical Trials Group Protocol 108. MEASURES. A 33-item battery assessing 7 dimensions of HRQOL: physical functioning, pain, energy, general health perceptions, disability, pulmonary symptoms, and constitutional symptoms. RESULTS. Analyses focused on changes in score from baseline to Day 7 (n = 145). Separate analyses for each dimension suggested a trend favoring CP versus TS, but using a Bonferroni correction no differences were statistically significant. O'Brien's global procedure for a test of no-treatment effect versus superiority of one treatment yielded P = 0.07. MANOVA did not reveal significant differences among treatment groups. A random effects model using fixed treatment and dimension effects and separate random effects for each person showed a significant overall treatment effect (P = 0.02); changes in scores for CP averaged 10 points greater than for TS. CONCLUSIONS. Random-effects models provide a flexible class of models for analyzing multidimensional quality of life data and estimating treatment effects because they borrow strength across dimensions.

AB - BACKGROUND. Current analytic methods applied to multidimensional health-related quality of life (HRQOL) data do not borrow strength across analyses and do not produce summary estimates of effect. OBJECTIVES. To compare a random effects modelling approach for the analysis of multidimensional HRQOL data to the following: (1) separate analyses for each dimension; (2) O'Brien's global test procedure; and (3) multivariate analysis of variance (MANOVA). RESEARCH DESIGN. Randomized clinical trial comparing 3 treatments (Trimethoprim-Sulfamethoxazole [TS], Dapsone-Trimethoprim [DT], and Clindamycin-Primaquine [CP] for Pneumocystis carinii pneumonia [PCP]). SUBJECTS. Patients with PCP enrolled in AIDS Clinical Trials Group Protocol 108. MEASURES. A 33-item battery assessing 7 dimensions of HRQOL: physical functioning, pain, energy, general health perceptions, disability, pulmonary symptoms, and constitutional symptoms. RESULTS. Analyses focused on changes in score from baseline to Day 7 (n = 145). Separate analyses for each dimension suggested a trend favoring CP versus TS, but using a Bonferroni correction no differences were statistically significant. O'Brien's global procedure for a test of no-treatment effect versus superiority of one treatment yielded P = 0.07. MANOVA did not reveal significant differences among treatment groups. A random effects model using fixed treatment and dimension effects and separate random effects for each person showed a significant overall treatment effect (P = 0.02); changes in scores for CP averaged 10 points greater than for TS. CONCLUSIONS. Random-effects models provide a flexible class of models for analyzing multidimensional quality of life data and estimating treatment effects because they borrow strength across dimensions.

KW - Analytic methods

KW - Clinical trial

KW - HIV/AIDS

KW - Quality of life

KW - Random effects

UR - http://www.scopus.com/inward/record.url?scp=0033087773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033087773&partnerID=8YFLogxK

U2 - 10.1097/00005650-199903000-00005

DO - 10.1097/00005650-199903000-00005

M3 - Article

VL - 37

SP - 249

EP - 258

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 3

ER -